Pandemic 2020
- Thread starter Jimdamick
- Start date
- Status
Budley Doright
Well-Known Member
it's like a light switch you aren't then boom! as i'm paying someone at thrift shop mentions 'wednesday is senior day 50% off'..i'm in all black mask coat beanie and sunglasses my hair up in the beanie which is blonde not gray..WTF? i don't have senior hands yet so WTF?So far so good here but like everything else I’m sure I’ll find out ........ growing old is great....said no one ever.
topcat
Well-Known Member
"Come die in South Dakota", new tourism ad. (not really)
www.theonion.com
South Dakota Unveils New ‘Come Die Here’ Tourism Campaign
PIERRE, SD—In an effort to attract visitors to a state that is home to some of the worst Covid-19 infection rates in the world, South Dakota officials launched a new tourism initiative Friday that will be centered around the slogan “Come Die Here.” “For years, people have flocked here to see...
www.theonion.com
someone else posted this yesterday and i'm like what about Colorado and Oregon? we have right to die"Come die in South Dakota", new tourism ad. (not really)
South Dakota Unveils New ‘Come Die Here’ Tourism Campaign
PIERRE, SD—In an effort to attract visitors to a state that is home to some of the worst Covid-19 infection rates in the world, South Dakota officials launched a new tourism initiative Friday that will be centered around the slogan “Come Die Here.” “For years, people have flocked here to see...
wow she is one crazy bitch..The Trump Plague Tree.
Highlights of this year's display -- coming during a global pandemic -- include a tribute to essential workers in the Red Room, including a light-up ceramic post office, and a tree with ornaments celebrating frontline workers, including a trash truck, scientist, caregiver, lab coat and nurse hat.
www.cnn.com
Highlights of this year's display -- coming during a global pandemic -- include a tribute to essential workers in the Red Room, including a light-up ceramic post office, and a tree with ornaments celebrating frontline workers, including a trash truck, scientist, caregiver, lab coat and nurse hat.
Melania Trump's White House holiday decor spotlights essential workers | CNN Politics
'Tis the holiday season at the White House. All of the halls, from the East Room to the Red Room, were decked by over 125 volunteers this weekend and unveiled Monday to feature classic holiday décor with an "America the Beautiful" theme for the Trumps' final Christmas in office.
DIY-HP-LED
Well-Known Member
‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19 | Science | AAAS (sciencemag.org)
This man in Ohio was among the tens of thousands who received Moderna’s experimental COVID-19 vaccine in a recent trial that demonstrated 94.1% efficacy.
UNIVERSITY OF CINCINATTI HEALTH
‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19
By Jon CohenNov. 30, 2020 , 7:00 AM
Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago.
More impressive still, Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. The company today plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines Agency.
The data released today bolster an interim report from the company two weeks ago that only analyzed 95 total cases but produced similarly impressive efficacy. “I would still like to see all of the actual data, but what we’ve seen so far is absolutely remarkable,” says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia who is a member of an independent committee of vaccine experts that advises FDA.
Moderna’s vaccine against SARS-CoV-2, the virus that causes COVID-19, relies on a novel technology that uses messenger RNA (mRNA) to code for a protein called spike that studs the surface of the pathogen. Pfizer and BioNTech have developed a similar mRNA vaccine against COVID-19 and also reported excellent results, with an efficacy of 95%, in the final analysis of their 45,000-person trial. In that study, which ended after 170 cases of COVID-19 were identified, only 10 severe cases occurred, and just one was in the vaccinated group.
Moderna and the Pfizer/BioNTech collaboration say their vaccines worked to about the same degree in all different groups, ethnicities, and genders. (More than 7000 participants were over age 65 and more than 5000 were under 65 but had diseases putting them at a higher risk of severe COVID-19; the study also included more than 11,000 people from communities of color.) That equal success is vital information for bodies trying to prioritize the use of the new vaccines, such as an advisory panel to the Centers for Disease Control and Prevention (CDC) that is meeting tomorrow. The committee’s recommendations influence CDC’s decisions about vaccine prioritization, but individual states come up with their own guidelines.
Moderna received $1 billion from the U.S. government’s Operation Warp Speed to help develop its mRNA vaccine. (Pfizer passed on such development money, but has signed an advanced purchase order for its vaccine with Warp Speed.) Moderna CEO Stéphane Bancel says all of the federal money went toward staging the clinical trials, and that without it, progress surely would have been delayed. Investors in May contributed another $1.3 billion to help the young company, which has no products on the market, build facilities to produce its vaccine.
Pfizer filed an EUA request for its vaccine last week, which led FDA to announce it will convene a meeting of its vaccine advisory committee to discuss the data in depth on 10 December. Bancel says FDA has told the company it might convene the committee again as early as 17 December to review its EUA application. He says the agency could issue an EUA 24 to 72 hours later.
Bancel imagines the Moderna vaccine, given its high efficacy against both mild and severe disease, will have the most impact if given to people at the greatest risk from SARS-CoV-2. “Give it to health care workers, give it to the elderly, give it to people with diabetes, overweight, heart disease,” he says. “A 25-year-old healthy man? Give him another vaccine.”
Moderna plans to charge $32 to $37 per dose of the vaccine in developed countries, Bancel says, but will have cheaper pricing for other parts of the world. The company is negotiating with the COVID-19 Vaccines Global Access Facility, a nonprofit that aims to reduce global vaccine inequities by purchasing and distributing approved products. “We want to have this vaccine available at a tiered price for low-income countries,” he says.
Bancel stresses that he wants other COVID-19 vaccines to succeed as well. “The world needs several manufacturers to make it to the finish line to stop this awful pandemic,” he says. U.K. pharma giant AstraZeneca, in partnership with the University of Oxford, has reported preliminary evidence of efficacy for its COVID-19 vaccine, as has the Gamaleya Research Institute of Epidemiology and Microbiology in Russia.
Moderna hopes to provide the U.S. government with 20 million doses by the end of the year, and Pfizer says it should have 50 million doses to split between the United States and other countries that made advanced purchase agreements.
This man in Ohio was among the tens of thousands who received Moderna’s experimental COVID-19 vaccine in a recent trial that demonstrated 94.1% efficacy.
UNIVERSITY OF CINCINATTI HEALTH
‘Absolutely remarkable’: No one who got Moderna’s vaccine in trial developed severe COVID-19
By Jon CohenNov. 30, 2020 , 7:00 AM
Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
Continuing the spate of stunning news about COVID-19 vaccines, the biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate in a press release today: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says, far above what many vaccine scientists were expecting just a few weeks ago.
More impressive still, Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. The company today plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines Agency.
The data released today bolster an interim report from the company two weeks ago that only analyzed 95 total cases but produced similarly impressive efficacy. “I would still like to see all of the actual data, but what we’ve seen so far is absolutely remarkable,” says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia who is a member of an independent committee of vaccine experts that advises FDA.
Moderna’s vaccine against SARS-CoV-2, the virus that causes COVID-19, relies on a novel technology that uses messenger RNA (mRNA) to code for a protein called spike that studs the surface of the pathogen. Pfizer and BioNTech have developed a similar mRNA vaccine against COVID-19 and also reported excellent results, with an efficacy of 95%, in the final analysis of their 45,000-person trial. In that study, which ended after 170 cases of COVID-19 were identified, only 10 severe cases occurred, and just one was in the vaccinated group.
Moderna and the Pfizer/BioNTech collaboration say their vaccines worked to about the same degree in all different groups, ethnicities, and genders. (More than 7000 participants were over age 65 and more than 5000 were under 65 but had diseases putting them at a higher risk of severe COVID-19; the study also included more than 11,000 people from communities of color.) That equal success is vital information for bodies trying to prioritize the use of the new vaccines, such as an advisory panel to the Centers for Disease Control and Prevention (CDC) that is meeting tomorrow. The committee’s recommendations influence CDC’s decisions about vaccine prioritization, but individual states come up with their own guidelines.
Moderna received $1 billion from the U.S. government’s Operation Warp Speed to help develop its mRNA vaccine. (Pfizer passed on such development money, but has signed an advanced purchase order for its vaccine with Warp Speed.) Moderna CEO Stéphane Bancel says all of the federal money went toward staging the clinical trials, and that without it, progress surely would have been delayed. Investors in May contributed another $1.3 billion to help the young company, which has no products on the market, build facilities to produce its vaccine.
Pfizer filed an EUA request for its vaccine last week, which led FDA to announce it will convene a meeting of its vaccine advisory committee to discuss the data in depth on 10 December. Bancel says FDA has told the company it might convene the committee again as early as 17 December to review its EUA application. He says the agency could issue an EUA 24 to 72 hours later.
Bancel imagines the Moderna vaccine, given its high efficacy against both mild and severe disease, will have the most impact if given to people at the greatest risk from SARS-CoV-2. “Give it to health care workers, give it to the elderly, give it to people with diabetes, overweight, heart disease,” he says. “A 25-year-old healthy man? Give him another vaccine.”
Moderna plans to charge $32 to $37 per dose of the vaccine in developed countries, Bancel says, but will have cheaper pricing for other parts of the world. The company is negotiating with the COVID-19 Vaccines Global Access Facility, a nonprofit that aims to reduce global vaccine inequities by purchasing and distributing approved products. “We want to have this vaccine available at a tiered price for low-income countries,” he says.
Bancel stresses that he wants other COVID-19 vaccines to succeed as well. “The world needs several manufacturers to make it to the finish line to stop this awful pandemic,” he says. U.K. pharma giant AstraZeneca, in partnership with the University of Oxford, has reported preliminary evidence of efficacy for its COVID-19 vaccine, as has the Gamaleya Research Institute of Epidemiology and Microbiology in Russia.
Moderna hopes to provide the U.S. government with 20 million doses by the end of the year, and Pfizer says it should have 50 million doses to split between the United States and other countries that made advanced purchase agreements.
Jimdamick
Well-Known Member
I consider this thread a time capsule in a way, one that can be read in the future by my fellow heads so they can get an understanding of what it was like too exist in this Age of COVID-19 in 2020.
This interview of Billie Eilish by Vanity Fair therefore should be be included.
She's cool
This interview of Billie Eilish by Vanity Fair therefore should be be included.
She's cool
Jimdamick
Well-Known Member
FUCK GOD, he/she/it is a murderer & that's a fucking fact
DIY-HP-LED
Well-Known Member
Thoughts and prayers, science is bad, I'm sure he's gonna refuse the vaccine for his state and pray the covid away. Considering how much trump won the state by did you expect any less, how about showing people how to pray in a mask. If their faith in God is so weak that they cannot skip their weekly brain washing sessions for a spell, they should consider atheism, it's safer.
A lot of republican governors are guilty of manslaughter and it can be proven in court, all someone has to do is indict them. Public officials must be held to account for their actions, if those actions or lack of them killed thousands of citizens. The federal government needs to issue a report on its own response, but also the response of all 50 states and criminal liability needs to be discussed at least and perhaps recommended.
Much of the future depends on winning the senate, then they might do things like issue reports on the covid response and regulating broadcasters and large social media companies
Crimes Against Humanity fits; and no he cannot be pardoned.
captainmorgan
Well-Known Member
More than 2,500 dead yesterday,maga.
captainmorgan
Well-Known Member
Unclebaldrick
Well-Known Member
It doesn't matter. Magats will just say that this is a way for the hospitals to cash in on the Jewish plot to forceably inject microchips into every American so they can put us all in concentration camps.
They are very dumb. Right @JoeBlow5823?
JoeBlow5823
Well-Known Member
So you think a vaccine would come with a microchip. Ok. But you dont think they want full control over technology in order to track everyone, only to trace the virus? C'mon MAN!
DIY-HP-LED
Well-Known Member
Just concentrate on keeping them out of power, even with thin majorities, but you also need to be proactive in addressing root economic concerns. The country is polarized and those who voted for Trump cannot be swayed, so there is little point in appeasing the hard core base, issues must be found that divide them. Racism and bigotry are the cement that binds the aggregate of grievance together, for most of them the issue is black and white, people that is. Economic and social stress exacerbate this and bring people's biases to the fore, everybody becomes an asshole on many levels when they are stressed out.
- Status